[HTML][HTML] Therapeutic drug monitoring of ganciclovir: where are we?
AG Märtson, AE Edwina, HY Kim… - Therapeutic Drug …, 2022 - journals.lww.com
Background: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
[HTML][HTML] Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
AG Märtson, AE Edwina, HY Kim… - Therapeutic Drug …, 2022 - ncbi.nlm.nih.gov
Background: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Therapeutic drug monitoring of ganciclovir: Where are we?
AG Märtson, AE Edwina, HY Kim… - Therapeutic Drug …, 2022 - research.rug.nl
PURPOSE: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
AG Märtson, AE Edwina, HY Kim… - Therapeutic Drug …, 2022 - ingentaconnect.com
Background: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
AG Märtson, AE Edwina, HY Kim… - Therapeutic Drug …, 2022 - europepmc.org
Background Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
[PDF][PDF] Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
AG Märtson, AE Edwina, HY Kim, M Knoester… - Ther Drug …, 2022 - lirias.kuleuven.be
Background: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
AG Märtson, AE Edwina, HY Kim… - Therapeutic drug …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Therapeutic drug monitoring of ganciclovir: where are we?
AG Märtson, AE Edwina, HY Kim, M Knoester, DJ Touw… - 2022 - cabidigitallibrary.org
Background: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
AG Martson, AE Edwina, HY Kim… - Therapeutic Drug …, 2022 - lirias.kuleuven.be
BACKGROUND: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …